Posts by Sandra Ansanay-Alex
Forum des 100 – Le Temps
Two BioAlps experts nominated Two Life Sciences experts, Dominique Truchot-Cardot and Alexandre Pauchard, are among the 100 personalities of the year in French-speaking Switzerland and have been selected by Le Temps Magazine for the Forum des 100. The conference will take place on 11 October 2022 at the Swiss Tech Convention Center. Dominique…
Read MoremachineMD raises CHF 3.2 Million
The MedTech startup is developing a medical device for the early diagnosis of neurological disorders including brain tumors via neuro-ophthalmic examinations. machineMD, from the Sitem StartUp Club (SSC), is a spin-off of the University Hospital of Bern, Inselspital, founded by Prof. Mathias Abegg, MD, PhD, and a team of entrepreneurs and medical device experts.…
Read MoreBiopôle Vanguard Accelerator
This six-month programme, supported by Biopôle SA and its partners, helps health-oriented projects to grow. The Vanguard Accelerator is a free six-month programme, run by Biopôle SA and its partners, to help digital-health-oriented projects supercharge their innovation and take their business strategy to the next level. This immersive programme is a unique opportunity for early-stage…
Read MoreCHUV, HUG and Inserm help Down syndrome patients to get better
The injection of the hormone GnRH improved the cognitive functions of several Down syndrome patients An Inserm team within the Lille neuroscience & cognition laboratory (Inserm/University of Lille/CHU of Lille), the Centre Hospitalier Universitaire Vaudois (CHUV) and The Hôpitaux Universitaires de Genève (HUG) have collaborated to test the efficacy of a therapy based on…
Read MoreParkinson’s Disease: AC Immune Receives a Grant from The Michael J. Fox Foundation
A new USD 0.5 million grant brings up to USD 3.7 million the total amount The Michael J. Fox Foundation awarded the Swiss company. AC Immune SA, a Lausanne-based clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that The Michael J. Fox Foundation for Parkinson’s Research (MJFF) awarded the Company a new…
Read MoreA wearable tissue health monitor
Sensawear wins a CHF 150,000 Venture Kick grant to develop its wearable tissue health monitor Sensawear has developed the world’s first truly wearable, textile-based, tissue oxygenation monitoring sensor using trusted, proven, non-invasive near-infrared spectroscopy. Specially integrated fiber optics will give users real-time feedback on deep tissue oxygen saturation without adding pressure against the skin.…
Read MoreMATWIN Accelerator Programme in Oncology
Apply before 20 November 2026 to the MATWIN Innovation Programme and boost your oncology innovation MATWIN supports innovative oncology projects through a tailored acceleration programme combining international expertise, strategic coaching and access to the unique UNICANCER network of industrial, academic and investment partners. By joining the MATWIN programme, you will have the opportunity to : About MATWIN Unique in Europe,…
Read MoreSightIn Health wins a CHF 150,000 Venture Kick grant
The Swiss start-up wants to develop an AI-SaaS to democratize the use and interpretation of ultrasound SightIn Health’s Machine Vision and Artificial Intelligence software enables anyone to expertly operate, interpret, and analyze point-of-care ultrasound – without the need for any prior training. The real-time AI guidance system helps operators find the correct anatomical scanning…
Read MoreDayOne Tech Accelerator presents its first cohort
The DayOne Tech Accelerator in the Canton of Jura has just announced its winners. Three Medtech startups are starting a 12-month programme. Experts will help to push them to a higher level. CNS Therapy (Zug): Drug-free pain treatment The company has developed the ability to treat chronic pain patients using neuromodulation and behavioral therapy.…
Read MoreAC BioScience closes a 4th seed-round of CHF 2.5 million
AC BioScience, a Biopôle-based clinical-stage biotech company pioneering the development of novel therapies in immuno-oncology and tumour vascular normalization, announces a fourth Seed Round for CHF 2.5 million. Founded by Andreas Schlaepfer and Professor Christian Auclair, AC BioSciences develops personalized molecular therapies designed to optimize efficiency or bolster the therapeutic benefit for particular groups…
Read More